Shots:
- Sanyou & Baiyunshan Xihe have entered into a strategic collaboration to co-develop novel radiopharmaceuticals & radiodiagnostic products by combining AI-driven drug discovery with nuclear medicine expertise
- As per the deal, Sanyou Bio will contribute its AI-STAL libraries & AI-Drug Accelerator platform for target molecule discovery, while Baiyunshan Xihe will lead radionuclide production, radiolabeling, preclinical development, GMP manufacturing, & clinical translation
- The companies aim to build an end-to-end innovation platform spanning AI-based molecular discovery through clinical translation, accelerating the development of differentiated theranostic radiopharmaceuticals
Ref: PRnewswire | Image: Sanyou & Baiyunshan Xihe | Press Release
Related News: CSPC Group and AstraZeneca Partner to Develop siRNA Drugs in ~$1.77B Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
